Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21812409 | 0.86 | AKR1C3 (0.48) | AKR1C3ACACBPDE10AKDM4EALDH1A1 | |
| SCHEMBL15205885 | 0.84 | LMNA (0.55) | AKR1C3PDE10AKDM4EGRIN2DGRIN3B | |
| SCHEMBL30473867 | 0.82 | ACACB (0.51) | AKR1C3ACACBPDE10AKDM4EALDH1A1 | |
| SCHEMBL20474651 | 0.82 | ACACB (0.51) | AKR1C3ACACBPDE10AKDM4EALDH1A1 | |
| SCHEMBL20474710 | 0.82 | ACACB (0.46) | AKR1C3ACACBPDE10AKDM4EALDH1A1 | |
| SCHEMBL13547453 | 0.80 | PDE10A (0.50) | AKR1C3ACACBPDE10AKDM4EALDH1A1 | |
| SCHEMBL30283050 | 0.80 | PDE10A (0.50) | AKR1C3ACACBPDE10AKDM4EALDH1A1 | |
| SCHEMBL25404700 | 0.79 | AKR1C3 (0.45) | AKR1C3ACACBPDE10AKDM4EALDH1A1 | |
| SCHEMBL29572264 | 0.79 | AKR1C3 (0.45) | AKR1C3ACACBPDE10AKDM4EALDH1A1 | |
| SCHEMBL23210947 | 0.78 | CHRM4 (0.47) | AKR1C3ACACBPDE10AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3585775-B1 | AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2022-04-06 | — | — | EP | disclosed |
| US-10392366-B2 | Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2019-08-27 | — | — | US | disclosed |
| WO-2018153849-A1 | AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2018-08-30 | — | — | WO | disclosed |
| US-20180237419-A1 | AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2018-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392366-B2 | Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | GPR119, GPR39, GPR139 | AKR1C3 2727/4885ACACB 907/4885PDE10A 1439/4885 |
| US-20180237419-A1 | AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, GIPR, GPR39 | AKR1C3 3873/4885ACACB 1569/4885PDE10A 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.